Human monoclonal antibodies to epidermal growth factor receptor
US6235883A · kind A · utility
346Cited by
0References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 5, 1997 |
| Grant date | May 22, 2001 |
| Priority date | — |
| Expiry date | May 5, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
In accordance with the present invention, there are provided fully human monoclonal antibodies against human epidermal growth factor receptor (EGF-r). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences from CDR1 through CDR3, are provided. Hybridomas expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.